Astrazeneca PLC (AZN) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Astrazeneca PLC stock price
Astrazeneca PLC latest news:
AstraZeneca ticks another box as U.S. approves severe asthma drug
* FDA clears Fasenra for patients aged 12 years and older. * AstraZeneca (AZN) prices maintenance dose below rivals. * AstraZeneca (AZN) product will vie with GSK's Nucala. By Ben Hirschler. AstraZeneca (AZN) has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it.
UPDATE 1-AstraZeneca ticks another box as U.S. approves severe asthma drug
* AstraZeneca product will vie with GSK's Nucala
(Adds details on pricing, competition, CEO comment)
UK Stocks-Factors to watch on Nov 15
Nov 15 (Reuters) - Britain's FTSE 100 index is seen opening down 4
points at 7,410.4 on Wednesday, according to financial bookmakers.
* ASTRAZENECA: Anglo-Swedish pharmaceutical firm AstraZeneca Plc on
Tuesday said the U.S. Food and Drug Administration approved its drug
Benralizumab, as an add-on treatment for patients with severe asthma aged 12
years and older.
* GOCMOPARE-ZPG: British company GoCompare has rejected a 460
million pound ($600 million) takeover approach made by
U.S. FDA approves AstraZeneca's asthma drug
Anglo-Swedish pharmaceutical firm AstraZeneca Plc (AZN) on Tuesday said the U.S. Food and Drug Administration approved its drug benralizumab, as an add-on treatment for patients with severe asthma aged 12 years and older. The asthma drug will be marketed under the name Fasenra in the United States. Fasenra is under regulatory review in the EU, Japan and several other countries, the company said.
BRIEF-AstraZeneca CEO still sees 2023 sales above $40 billion at today's FX
AstraZeneca CEO Pascal Soriot told reporters: * working to duplicate quality control systems so can release drugs in EU if hard Brexit. * sees high growth rate in China sustainable for next 2-3 years. * long term plan confirms we can get to $40-41 billion sales target by 2023 at current exchange rates Further company coverage:
AstraZeneca Q3 sales weak as it waits for medicine to work
AstraZeneca's(AZN) drug sales fell 3 percent in the third quarter, hit again by generic competition to former blockbusters like cholesterol pill Crestor, as it looks to new cancer treatments to revive its fortunes. Total revenue, however, rose 9 percent to $6.23 billion, helped by a $997 million payment from Merck & Co (MRK), which struck a cancer drug partnership deal with the British group in July.
BRIEF-Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca
Upsher-Smith Laboratories LLC: * Upsher-Smith Laboratories says co's parent Sawai Pharmaceutical (SWPIF) entered agreement with AstraZeneca (AZN) to manufacture & market migraine medication in Japan. * Upsher-Smith Laboratories - agreement is to manufacture, market Zomig Tablets 2.5 mg & Zomig Rapid Melt Tablets 2.5 mg.
BRIEF-AstraZeneca and Merck submit application for breast cancer drug in Japan
* ASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN
WITH A SECOND REGULATORY SUBMISSION
BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties
* Flexion Therapeutics Inc - on September 8, co sent a
notice of termination to Astrazeneca AB regarding an out-license
agreement between parties
UK Stocks-Factors to watch on Sept 11
Sept 11 (Reuters) - Britain's FTSE 100 index is seen opening up 28
points at 7,405 on Monday, according to financial bookmakers.
* AstraZeneca: Two AstraZeneca drugs tackling lung cancer in
different ways delivered encouraging results on Saturday, helping the British
group offset July's big clinical trial setback in the disease.
* SHELL: Shell's Nigerian business has signed a $300 mln deal with
Shoreline Energy to develop gas pipeline infrastructure in the country,
AstraZeneca CEO, worried by Brexit, not signing UK government letter
MADRID (Reuters) - AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government's strategy.
AstraZeneca shares tick higher on lung cancer drug study results
U.S. shares of AstraZeneca PLC rose in the extended session Friday after the drug maker released promising results from a lung cancer drug study. AstraZeneca American depositary receipts rose 2% to $32.90 after hours. The company said a late-stage clinical trial of its drug Tagrisso improved progression-free survival rates in certain lung cancer patients to a median 18.9 months compared with the 10.2 months seen in patients given standard of care treatment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UK Stocks-Factors to watch on Sept 7
Sept 7 (Reuters) - Britain's FTSE 100 index is seen opening 10
points higher at 7354.13 on Thursday, according to financial bookmakers.
* RBS: Britain's financial regulator should release a leaked report about
Royal Bank of Scotland that alleged many companies suffered from
"inappropriate action" by its Global Restructuring Group unit, a senior British
* ASTRAZENECA: A new kind of injectable biotech treatment for severe asthma
from AstraZeneca and Amgen promises t
Atlantic Power CorporationAT
Atlas Resource PartnersARP
Atlas Resource PartnersARP^D
Atlas Resource PartnersARP^E
Atmos Energy CorporationATO
AU Optronics CorpAUO